Cancer biomarker discovery and validation

Translational Cancer Research

Volumn 4, Issue 3, 2015, Pages 256-269

  Goossens, Nicolas ^a,b   Nakagawa, Shigeki ^a   Sun, Xiaochen ^a   Hoshida, Yujin ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Biomarker; Cancer; Companion biomarker; Drug response biomarker; Prognosis

Indexed keywords

CETUXIMAB; ESTROGEN RECEPTOR; TAMOXIFEN; TUMOR MARKER;

BLADDER CANCER; BREAST CANCER; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CELLULAR DISTRIBUTION; CHEMICAL MODIFICATION; CHRONIC MYELOID LEUKEMIA; CLINICAL DECISION MAKING; COLORECTAL CANCER; DIAGNOSTIC ACCURACY; GENE EXPRESSION; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LUNG ADENOCARCINOMA; MELANOMA; METASTATIC BREAST CANCER; MOLECULARLY TARGETED THERAPY; NON SMALL CELL LUNG CANCER; OVARY CANCER; PRACTICE GUIDELINE; PROMYELOCYTIC LEUKEMIA; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW;

EID: 84962776171     PISSN: 2218676X     EISSN: 22196803     Source Type: Journal    
DOI: 10.3978/j.issn.2218-676X.2015.06.04     Document Type: Review

References (94)

1. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med 2015;372:793-5
2. Tzoulaki I, Siontis KC, Ioannidis JP. Prognostic effect size of cardiovascular biomarkers in datasets from observational studies versus randomised trials: meta-epidemiology study. BMJ 2011;343:d6829
3. Ioannidis JP, Panagiotou OA. Comparison of effect sizes associated with biomarkers reported in highly cited individual articles and in subsequent meta-analyses. JAMA 2011;305:2200-10
4. Paul SM, Mytelka DS, Dunwiddie CT, et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov 2010;9:203-14
5. Committee on the Review of Omics-Based Tests for Predicting Patient Outcomes in Clinical Trials, Board on Health Care Services, Board on Health Sciences Policy, et al. Evolution of Translational Omics: Lessons Learned and the Path Forward. National Academies Press 2012
6. Lassere MN. The Biomarker-Surrogacy Evaluation Schema: a review of the biomarker-surrogate literature and a proposal for a criterion-based, quantitative, multidimensional hierarchical levels of evidence schema for evaluating the status of biomarkers as surrogate endpoints. Stat Methods Med Res 2008;17:303-40
7. World Health Organization. Biomarkers in risk assessment: Validity and validation. WHO 2001
8. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92
9. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84
10. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-72
11. Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-17
12. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817-26
13. Imperiale TF, Ransohoff DF, Itzkowitz SH. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 2014;371:187-8
14. Simon R, Roychowdhury S. Implementing personalized cancer genomics in clinical trials. Nat Rev Drug Discov 2013;12:358-69
15. McShane LM, Cavenagh MM, Lively TG, et al. Criteria for the use of omics-based predictors in clinical trials. Nature 2013;502:317-20
16. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 2009;101:1446-52
17. Hayes DF. Biomarker validation and testing. Mol Oncol 2015;9:960-6
18. Schully SD, Carrick DM, Mechanic LE, et al. Leveraging biospecimen resources for discovery or validation of markers for early cancer detection. J Natl Cancer Inst 2015;107:djv012
19. Kelloff GJ, Sigman CC. Cancer biomarkers: selecting the right drug for the right patient. Nat Rev Drug Discov 2012;11:201-14
20. Simon R. Clinical trials for predictive medicine: new challenges and paradigms. Clin Trials 2010;7:516-24
21. Parkinson DR, McCormack RT, Keating SM, et al. Evidence of clinical utility: an unmet need in molecular diagnostics for patients with cancer. Clin Cancer Res 2014;20:1428-44
22. Sawyers CL, van't Veer LJ. Reliable and effective diagnostics are keys to accelerating personalized cancer medicine and transforming cancer care: a policy statement from the american association for cancer research. Clin Cancer Res 2014;20:4978-81
23. Poste G. Bring on the biomarkers. Nature 2011;469:156-7
24. Ransohoff DF, Gourlay ML. Sources of bias in specimens for research about molecular markers for cancer. J Clin Oncol 2010;28:698-704
25. Altman DG, McShane LM, Sauerbrei W, et al. Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. BMC Med 2012;10:51
26. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med 2007;147:573-7
27. Bossuyt PM, Reitsma JB, Bruns DE, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. BMJ 2003;326:41-4
28. Hoshida Y, Villanueva A, Kobayashi M, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008;359:1995-2004
29. Hoshida Y, Villanueva A, Sangiovanni A, et al. Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis. Gastroenterology 2013;144:1024-30
30. King LY, Canasto-Chibuque C, Johnson KB, et al. A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration. Gut 2014. [Epub ahead of print]
31. Fuchs BC, Hoshida Y, Fujii T, et al. Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma. Hepatology 2014;59:1577-90
32. Taube SE, Clark GM, Dancey JE, et al. A perspective on challenges and issues in biomarker development and drug and biomarker codevelopment. J Natl Cancer Inst 2009;101:1453-63
33. Watson RW, Kay EW, Smith D. Integrating biobanks: addressing the practical and ethical issues to deliver a valuable tool for cancer research. Nat Rev Cancer 2010;10:646-51
34. National Cancer Institute. NCI Best Practices for Biospecimen Resources. Available online: http://biospecimens.cancer.gov/bestpractices/2011-NCIbestpractices.pdf
35. Massett HA, Atkinson NL, Weber D, et al. Assessing the need for a standardized cancer HUman Biobank (caHUB): findings from a national survey with cancer researchers. J Natl Cancer Inst Monogr 2011;2011:8-15
36. Baggerly KA, Morris JS, Coombes KR. Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments. Bioinformatics 2004;20:777-85
37. Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359:572-7
38. Hernández B, Parnell A, Pennington SR. Why have so few proteomic biomarkers "survived" validation? (Sample size and independent validation considerations). Proteomics 2014;14:1587-92
39. Dupuy A, Simon RM. Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. J Natl Cancer Inst 2007;99:147-57
40. Mesirov JP. Computer science. Accessible reproducible research. Science 2010;327:415-6
41. Barrett T, Troup DB, Wilhite SE, et al. NCBI GEO: archive for high-throughput functional genomic data. Nucleic Acids Res 2009;37:D885-90
42. Sequist LV, Heist RS, Shaw AT, et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol 2011;22:2616-24
43. Zhang Z, Chan DW. The road from discovery to clinical diagnostics: lessons learned from the first FDA-cleared in vitro diagnostic multivariate index assay of proteomic biomarkers. Cancer Epidemiol Biomarkers Prev 2010;19:2995-9
44. Koscielny S. Why most gene expression signatures of tumors have not been useful in the clinic. Sci Transl Med 2010;2:14ps2
45. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009
46. Chia SK, Bramwell VH, Tu D, et al. A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen. Clin Cancer Res 2012;18:4465-72
47. Geiss GK, Bumgarner RE, Birditt B, et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol 2008;26:317-25
48. FDA. Laboratory Developed Tests. Available online: http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/ucm407296.htm
49. Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 2014;311:1998-2006
50. Hegde M, Bale S, Bayrak-Toydemir P, et al. Reporting incidental findings in genomic scale clinical sequencing-a clinical laboratory perspective: a report of the Association for Molecular Pathology. J Mol Diagn 2015;17:107-17
51. Mardis ER. The $1,000 genome, the $100,000 analysis? Genome Med 2010;2:84
52. April C, Klotzle B, Royce T, et al. Whole-genome gene expression profiling of formalin-fixed, paraffin-embedded tissue samples. PLoS One 2009;4:e8162
53. Reis PP, Waldron L, Goswami RS, et al. mRNA transcript quantification in archival samples using multiplexed, color-coded probes. BMC Biotechnol 2011;11:46
54. Kojima K, April C, Canasto-Chibuque C, et al. Transcriptome profiling of archived sectioned formalin-fixed paraffin-embedded (AS-FFPE) tissue for disease classification. PLoS One 2014;9:e86961
55. Crowley E, Di Nicolantonio F, Loupakis F, et al. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol 2013;10:472-84
56. Plaks V, Koopman CD, Werb Z. Cancer. Circulating tumor cells. Science 2013;341:1186-8
57. Thierry AR, Mouliere F, El Messaoudi S, et al. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nat Med 2014;20:430-5
58. Smerage JB, Barlow WE, Hortobagyi GN, et al. Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol 2014;32:3483-9
59. Guo QJ, Miils JN, Mason N, et al. Abstract A47: MicroRNA-510 as a predictive marker for response to platinum-based chemotherapy in triple negative breast cancer. Clin Cancer Res 2015;A47
60. Simmer F, Dijkstra J, Venderbosch S, et al. Abstract 534: MicroRNA-143 is a putative predictive biomarker for 5-FU-based chemotherapy in patients with metastatic colorectal cancer. Cancer Res 2014;74:534
61. Teutsch SM, Bradley LA, Palomaki GE, et al. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group. Genet Med 2009;11:3-14
62. Dowsett M, Cuzick J, Wale C, et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol 2010;28:1829-34
63. Febbo PG, Ladanyi M, Aldape KD, et al. NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. J Natl Compr Canc Netw 2011;9:S1-32; quiz S33
64. Home-brew tests need regulation. Nature 2014;512:5
65. Rubin EH, Allen JD, Nowak JA, et al. Developing precision medicine in a global world. Clin Cancer Res 2014;20:1419-27
66. National Comprehensive Cancer Network. About the NCCN Biomarkers Compendium®. Available online: http://www.nccn.org/professionals/biomarkers/default.aspx
67. Birkeland ML, McClure JS. Optimizing the Clinical Utility of Biomarkers in Oncology: The NCCN Biomarkers Compendium. Arch Pathol Lab Med 2015;139:608-11
68. Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013;31:3997-4013
69. FDA. List of Cleared or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools). Available online: http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/ucm301431.htm
70. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-97
71. Jordan VC. Selective estrogen receptor modulation: concept and consequences in cancer. Cancer Cell 2004;5:207-13
72. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-34
73. Dematteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009;373:1097-104
74. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346:645-52
75. Tallman MS, Andersen JW, Schiffer CA, et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997;337:1021-8
76. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol 2011;12:175-80
77. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-94
78. Chapman PB, Hauschild A, Robert C, et al. I Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16
79. Mamounas EP, Tang G, Fisher B, et al. Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. J Clin Oncol 2010;28:1677-83
80. Nguyen HG, Welty CJ, Cooperberg MR. Diagnostic associations of gene expression signatures in prostate cancer tissue. Curr Opin Urol 2015;25:65-70
81. You YN, Rustin RB, Sullivan JD. Oncotype DX® colon cancer assay for prediction of recurrence risk in patients with stage II and III colon cancer: A review of the evidence. Surg Oncol 2015;24:61-6
82. Newman AM, Bratman SV, To J, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med 2014;20:548-54
83. Schultz NA, Dehlendorff C, Jensen BV, et al. MicroRNA biomarkers in whole blood for detection of pancreatic cancer. JAMA 2014;311:392-404
84. Rutgers E, Piccart-Gebhart MJ, Bogaerts J, et al. Baseline results of the eortc 10041/mindact trial (microarray in node 0-3 positive disease may avoid chemotherapy). Eur J Cancer 2013;49:S464-5
85. Sharfstein J. FDA regulation of laboratory-developed diagnostic tests: protect the public, advance the science. JAMA 2015;313:667-8
86. Evans JP, Watson MS. Genetic testing and FDA regulation: overregulation threatens the emergence of genomic medicine. JAMA 2015;313:669-70
87. Marx V. Biology: The big challenges of big data. Nature 2013;498:255-60
88. Rehm HL, Berg JS, Brooks LD, et al. Clingen-the clinical genome resource. N Engl J Med 2015;372:2235-42
89. National Humane Genome Research Institute. Electronic Medical Records and Genomics (eMERGE) Network. Available online: http://www.genome.gov/27540473
90. Kannry JL, Williams MS. Integration of genomics into the electronic health record: mapping terra incognita. Genet Med 2013;15:757-60
91. Ratner M. Myriad decision aftershocks ripple through biotech. Nat Biotechnol 2013;31:663-5
92. Harrison C. Patenting natural products just got harder. Nat Biotechnol 2014;32:403-4
93. Cole P. Patentability of Genes: A European Union Perspective. Cold Spring Harb Perspect Med 2014;5:a020891
94. Harrison C. Patent watch: Australian court upholds Myriad's gene patent. Nat Rev Drug Discov 2014;13:805